Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bristol-Myers Squibb Reports First Quarter Financial Results
April 26, 2018 6:59 AM EDTIncreases First Quarter Revenues 5% to $5.2 Billion Posts First Quarter GAAP EPS of $0.91 and Non-GAAP EPS of $0.94 Achieves Important Clinical and Regulatory Milestones in Oncology Opdivo plus Yervoy Approved in the U.S. for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Opdivo Four-Week Dosing Approved in the U.S. and Europe Applications for Opdivo plus Yervoy for Previously Treated Patients with MSI-H or dMMR Metastatic... More
